Neurology Central

DCVax®-L as a potential vaccine against glioblastoma

Northwest Biotherapeutics (MD, USA) have announced the publication of interim, blinded survival data from its Phase III clinical trial of DCVax®-L for newly diagnosed glioblastoma. Researchers believe that addition of DCVax-L to standard therapy is feasible and safe in glioblastoma patients and may extend survival.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.